Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials

被引:26
|
作者
Niraula, Saroj [1 ,2 ]
Gyawali, Bishal [3 ]
机构
[1] Univ Manitoba, Sect Med Oncol & Hematol, Dept Internal Med, Winnipeg, MB, Canada
[2] CancerCare Manitoba, Winnipeg, MB, Canada
[3] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
关键词
Breast cancer; Herceptin; Duration; Adjuvant; CHEMOTHERAPY;
D O I
10.1007/s10549-018-4967-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundOne year of adjuvant trastuzumab, chosen empirically, improves survival of women with early-stage, Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Two years of trastuzumab does not improve efficacy but increases cost, inconvenience, and adverse effects. We aimed to evaluate if less than 1year of adjuvant trastuzumab retained efficacy while reducing toxicities and cost.MethodsWe performed a pooled analyses of efficacy and toxicity from Randomized Controlled Trials (RCTs) comparing 1year of trastuzumab to shorter durations in adjuvant treatment of HER2-positive breast cancer. Hazard Ratios (HR) for Overall Survival (OS) and Disease-Free Survival (DFS), and Odds Ratios (OR) for cardiac events with respective 95% Confidence Intervals (CI) were weighted using generic inverse variance approach and pooled in meta-analyses using random effects models with RevMan 5.3 software. Sub-group analyses of outcomes based on Estrogen Receptor (ER) and nodal status were performed.ResultsFive RCTs involving approximately 12,000 patients qualifiedthree assessing 6months and two assessing 9weeks of trastuzumab compared to 1year. All RCTs were designed to test non-inferiority of the shorter treatment. One year of trastuzumabresulted into better OS (pooled HR 1.23, 95% CI 1.07-1.42) and DFS (pooled HR 1.21, 95% CI 1.09-1.36) in overall population, but the benefit of longer treatment was statisticallyinsignificant in node negative (HR 1. 20, p=0.11), and ER positive disease (HR 1.15, p=0.09). Odds ratio for cardiac events was significantly higher with the longer duration (OR 2.48, p<0.001).ConclusionOne year of trastuzumab for adjuvant treatment of breast cancer improves outcomes compared to shorter treatments in overall population. Cardiotoxicity is increased with the longer treatment.
引用
收藏
页码:103 / 109
页数:7
相关论文
共 50 条
  • [1] Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials
    Saroj Niraula
    Bishal Gyawali
    Breast Cancer Research and Treatment, 2019, 173 : 103 - 109
  • [2] Trastuzumab in the adjuvant treatment of early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials
    Dahabreh, Issa J.
    Linardou, Helen
    Siannis, Fotios
    Fountzilas, George
    Murray, Samuel
    ONCOLOGIST, 2008, 13 (06): : 620 - 630
  • [3] Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
    Yin, Wenjin
    Jiang, Yiwei
    Shen, Zhenzhou
    Shao, Zhimin
    Lu, Jinsong
    PLOS ONE, 2011, 6 (06):
  • [4] Efficacy and safety of shorter duration of adjuvant trastuzumab for patients with HER2 positive early breast cancer: A meta-analysis of randomized controlled trials
    Li, J.
    Wang, G.
    Wu, Q.
    Chen, C.
    Tu, Y.
    Yao, F.
    Wei, W.
    Sun, S.
    Santa-Maria, C. A.
    Geng, P.
    CANCER RESEARCH, 2019, 79 (04)
  • [5] Extended duration of adjuvant aromatase inhibitor in breast cancer: a meta-analysis of randomized controlled trials
    Clement, Zackariah
    Kollias, James
    Bingham, Janne
    Whitfield, Robert
    Bochner, Melissa
    GLAND SURGERY, 2018, 7 (05) : 449 - 457
  • [6] Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
    Gustavo A Viani
    Sergio L Afonso
    Eduardo J Stefano
    Ligia I De Fendi
    Francisco V Soares
    BMC Cancer, 7
  • [7] Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
    Viani, Gustavo A.
    Afonso, Sergio L.
    Stefano, Eduardo J.
    De Fendi, Ligia I.
    Soares, Francisco V.
    BMC CANCER, 2007, 7 (1)
  • [8] Adjuvant Denosumab treatment in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials
    Mastrantoni, Luca
    Garufi, Giovanna
    Di Monte, Elena
    Maliziola, Noemi
    Pasqualoni, Mariangela
    Pontolillo, Letizia
    Pannunzio, Sergio
    Cannizzaro, Maria Chiara
    Di Bello, Armando
    Fabi, Alessandra
    Palazzo, Antonella
    Bria, Emilio
    Tortora, Giampaolo
    Orlandi, Armando
    CANCER RESEARCH, 2023, 83 (05)
  • [9] Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis of Randomized Controlled Trials
    Budach, Wilfried
    Bolke, Edwin
    Matuschek, Christiane
    BREAST CARE, 2015, 10 (04) : 240 - 245
  • [10] Additional adjuvant capecitabine in early breast cancer patients: a meta-analysis of randomized controlled trials
    Zhou, Wenqi
    Cao, Yong
    Gou, Ping
    Zeng, Xiaohua
    Hu, Xiaolei
    Lin, Zhousheng
    Ye, Changsheng
    Chen, Lujia
    Yao, Guangyu
    FUTURE ONCOLOGY, 2021, 17 (35) : 4993 - 5002